XML 124 R55.htm IDEA: XBRL DOCUMENT
v3.23.1

Equity (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2022
Disclosure of equity [abstract] |
Schedule disclosing information related to movement in the share capital |
(USD millions) |  | Jan 1, 2020 |  | Movement in year |  | Dec 31, 2020 |  | Movement in year |  | Dec 31, 2021 |  | Movement in year |  | Dec 31, 2022 |
Share capital 1 |  | 936 |  | -23 |  | 913 |  | -12 |  | 901 |  | -11 |  | 890 |
Treasury shares |  | -80 |  | 27 |  | -53 |  | 5 |  | -48 |  | -44 |  | -92 |
Outstanding share capital |  | 856 |  | 4 |  | 860 |  | -7 |  | 853 |  | -55 |  | 798 |
1 The Novartis AG share capital consists of registered shares with a nominal value of CHF 0.50 each. No authorized and conditional capital exists.
Schedule disclosing information related to movement in the shares |
|  |  |  | 2022 |  | 2021 |  | 2020 |
Number of outstanding shares (in millions) |  | Note |  | Total Novartis shares |  | Total treasury shares1 |  | Total outstanding shares |  | Total Novartis shares |  | Total treasury shares1 |  | Total outstanding shares |  | Total Novartis shares |  | Total treasury shares1 |  | Total outstanding shares |
Balance at beginning of year |  |  |  | 2 434.4 |  | -199.5 |  | 2 234.9 |  | 2 467.0 |  | -210.2 |  | 2 256.8 |  | 2 527.3 |  | -262.3 |  | 2 265.0 |
Shares canceled for capital reduction 2 |  |  |  | -30.7 |  | 30.7 |  |  |  | -32.6 |  | 32.6 |  |  |  | -60.3 |  | 60.3 |  |  |
Shares acquired to be canceled 3 |  |  |  |  |  | -126.2 |  | -126.2 |  |  |  | -30.7 |  | -30.7 |  |  |  | -32.6 |  | -32.6 |
Other share purchases 4 |  |  |  |  |  | -1.4 |  | -1.4 |  |  |  | -1.5 |  | -1.5 |  |  |  | -1.7 |  | -1.7 |
Exercise of options and employee transactions 5 |  | 18.9 |  |  |  | 1.9 |  | 1.9 |  |  |  | 0.6 |  | 0.6 |  |  |  | 14.7 |  | 14.7 |
Equity-based compensation 5 |  |  |  |  |  | 10.4 |  | 10.4 |  |  |  | 9.6 |  | 9.6 |  |  |  | 11.0 |  | 11.0 |
Shares delivered to Alcon employees |  |  |  |  |  | 0.0 |  | 0.0 |  |  |  | 0.1 |  | 0.1 |  |  |  | 0.4 |  | 0.4 |
Total movements |  |  |  | -30.7 |  | -84.6 |  | -115.3 |  | -32.6 |  | 10.7 |  | -21.9 |  | -60.3 |  | 52.1 |  | -8.2 |
Balance at end of year |  |  |  | 2 403.7 |  | -284.1 |  | 2 119.6 |  | 2 434.4 |  | -199.5 |  | 2 234.9 |  | 2 467.0 |  | -210.2 |  | 2 256.8 |
1 Approximately 99.0 million treasury shares (2021: 102.5 million; 2020: 103.0 million) are held in Novartis entities that restrict their availability for use.
2 Novartis reduced its share capital by canceling shares that were repurchased on the SIX Swiss Exchange second trading line during previous years.
3 Shares repurchased on the SIX Swiss Exchange second trading line under a CHF 10 billion share buyback authority approved at the 2019 Annual General Meeting (AGM) for transactions after February 28, 2019, until March 2, 2021. Transactions after March 2, 2021, were executed under the CHF 10 billion share buyback authority approved at the 2021 AGM and the additional CHF 10 billion authority approved at the 2022 AGM.
4 Shares acquired from employees, which were previously granted to them under the respective equity-based participation plans
5 Shares delivered as a result of options being exercised and physical share deliveries related to equity-based participation plans
Schedule disclosing information related to Dividend |
|  | 2022 |  | 2021 |  | 2020 |
Dividend per share (in CHF) |  | 3.10 |  | 3.00 |  | 2.95 |
Total dividend payment (in USD billion) |  | 7.5 |  | 7.4 |  | 7.0 |
Schedule disclosing information related treasury shares movements |
|  |  |  | 2022 |  | 2021 |  | 2020 |
|  | Note |  | Number of outstanding shares (in millions) |  | Equity impact USD m |  | Number of outstanding shares (in millions) |  | Equity impact USD m |  | Number of outstanding shares (in millions) |  | Equity impact USD m |
Shares acquired to be canceled 1 |  |  |  | -126.2 |  | -10 787 |  | -30.7 |  | -2 775 |  | -32.6 |  | -2 897 |
Other share purchases 2 |  |  |  | -1.4 |  | -123 |  | -1.5 |  | -145 |  | -1.7 |  | -159 |
Purchase of treasury shares |  |  |  | -127.6 |  | -10 910 |  | -32.2 |  | -2 920 |  | -34.3 |  | -3 056 |
Exercise of options and employee transactions 3 |  | 18.9 |  | 1.9 |  | 88 |  | 0.6 |  | 39 |  | 14.7 |  | 806 |
Equity-based compensation 4 |  |  |  | 10.4 |  | 854 |  | 9.6 |  | 745 |  | 11.0 |  | 730 |
Shares delivered to Alcon employees |  |  |  | 0.0 |  | 5 |  | 0.1 |  | 17 |  | 0.4 |  | 30 |
Total |  |  |  | -115.3 |  | -9 963 |  | -21.9 |  | -2 119 |  | -8.2 |  | -1 490 |
1 Shares repurchased on the SIX Swiss Exchange second trading line under a CHF 10 billion share buyback authority approved at the 2019 Annual General Meeting (AGM) for transactions after February 28, 2019, until March 2, 2021. Transactions after March 2, 2021, were executed under the CHF 10 billion share buyback authority approved at the 2021 AGM and the additional CHF 10 billion authority approved at the 2022 AGM.
2 Shares acquired from employees, which were previously granted to them under the respective equity-based participation plans
3 Shares delivered as a result of options being exercised related to equity-based participation plans and the delivery of treasury shares. The average share price of the shares delivered was significantly below market price, reflecting the strike price of the options exercised.
4 Equity-settled share-based compensation is expensed in the consolidated income statement in accordance with the vesting period of the share-based compensation plans. The value for the shares and options granted is credited to consolidated equity over the respective vesting period. In addition, tax benefits arising from tax-deductible amounts exceeding the expense recognized in the income statement are credited to equity.

X
- References No definition available. + Details
Name: | nvs_DisclosureOfEquityAbstract
Namespace Prefix: | nvs_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | nvs_DividendTableTextBlock
Namespace Prefix: | nvs_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | nvs_MovementInTheShareCapitalTableTextBlock
Namespace Prefix: | nvs_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | nvs_MovementInTheShareslTableTextBlock
Namespace Prefix: | nvs_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | nvs_SummaryOfTreasurySharesMovementsTableTextBlock
Namespace Prefix: | nvs_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration